FDA Weighs Peptide Regulation Amid Safety Concerns

The FDA is holding a two-day advisory committee meeting to decide whether certain peptides (BPC-157, TB-500, and five others) can be compounded by licensed pharmacies and sold by prescription, despite FDA scientists' recommendation against approval due to lack of robust human clinical trial data. The decision will determine market access for a category that has grown via social media marketing but lacks safety and efficacy evidence.

This Wire brief sits within Fusion42's coverage of Digital Health. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.